All In Biotech

Drug Trial Radar · NCT07104643

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of TYK-00540 Combined With Enzalutamide in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) That Has Failed Previous Novel Endocrine Therapy

Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Aug 2025

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy

Conditions

  • mCRPC

Interventions

  • TYK-00540Drug

    Take the specified dose (20mg or 30mg) orally twice a day. Take it on an empty stomach in the morning with about 200 mL of warm water.

  • EnzalutamideDrug

    Take orally, 160mg each time, once a day. Take orally with or without meals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experience one or more adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
  2. Dose Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
  3. Maximum tolerated dose(MTD)Time frame: Within 28 days of the first dose
  4. Recommended Phase 2 Dose(RP2D)Time frame: Within 28 days of the last patient dosed in escalation stage
  5. Progression-free survival (rPFS)Time frame: Up to approximately 21 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.